Long-term outcomes and clinical phenotypes associated with best response to low dose alemtuzumab in cutaneous T-cell lymphoma

Long-term outcomes and clinical phenotypes associated with best response to low dose alemtuzumab in cutaneous T-cell lymphoma

Abstract Cutaneous T-cell lymphomas (CTCL) have in common malignant T-lymphocyte infiltration in the skin. Low dose alemtuzumab (LDA) appears to be an effective treatment for leukemic disease, but in the absence of clinical trials, there is need for improved characterization of patients with CTCL mo...

Full description

Saved in:
Bibliographic Details
Main Authors: Cecilia Larocca, Ai-Tram N. Bui, John T. O’Malley, Anita Giobbie-Hurder, Marianne Tawa, Jessica E. Teague, Rachael A. Clark, Corey Cutler, Eric Jacobsen, David C. Fisher, Thomas S. Kupper, Nicole R. LeBoeuf
Format: Article
Language:English
Published: Nature Publishing Group 2025-04-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-025-01237-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41408-025-01237-5

Similar Items